Abstract 4297
Background
Anxiety and distress may be experienced by cancer patients diagnosed with melanoma throughout their diagnosis and treatment. Beaumont Hospital, Dublin is a designated cancer centre and a proposal to develop an onsite melanoma patient support group (MPSG) in collaboration with the Skin Oncology CNSp, and the Cancer Nurse, Daffodil Centre, Beaumont Hospital was agreed. Aims/Objectives: To assess the interest in attending a professionally facilitated MPSG. To ascertain what type of group would benefit most. To ascertain the themes required to meet the needs of the group. To offer a supportive, safe environment for meeting and sharing experiences. To create an awareness of the support required by patients diagnosed with melanoma.
Methods
Initial planning meeting between the Skin Oncology CNS and the Cancer Nurse, resulted in an agreement to develop a MPSG. A target population was identified and the practicalities and commitment involved in co-facilitating a support group were identified. Group governance was developed. An expression of interest letter and a questionnaire was sent to the target population, specific themes were incorporated to assist development of the support group and manage its format and content.
Results
Patient responses identified a format for the support group incorporating educational and emotional support. Group rules were established and adhered to, with regular evaluation and discussion taking place allowing change to be incorporated as required. Six meetings took place in 2018/2019.
Conclusions
Future plans include: Maintain stability of the group. Continue meeting every two months. Attract new members. Review of group by questionnaire in relation to specific patient interests.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract